Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19206066 | 0.85 | DRD2 (0.53) | ALDH1A1KDM4ETDP1HPGDHTT | |
| SCHEMBL17099410 | 0.84 | CCR8 (0.55) | ALDH1A1KDM4ECCR8DRD2ADRA1A | |
| SCHEMBL19206090 | 0.84 | CCR8 (0.51) | ALDH1A1KDM4ETDP1HPGDHTT | |
| SCHEMBL19206067 | 0.84 | SIGMAR1 (0.57) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL19206093 | 0.83 | ALDH1A1 (0.60) | ALDH1A1LMNAKDM4ETDP1HPGD | |
| SCHEMBL19206073 | 0.82 | ALDH1A1 (0.51) | ALDH1A1LMNAKDM4ETDP1HPGD | |
| SCHEMBL17055906 | 0.73 | CCR8 (0.62) | KDM4ECCR8 | |
| SCHEMBL17099425 | 0.73 | CCR8 (0.59) | ALDH1A1LMNAKDM4ECCR8 | |
| SCHEMBL17099358 | 0.73 | KDM4E (0.63) | ALDH1A1LMNAKDM4ETDP1HPGD | |
| SCHEMBL6501384 | 0.72 | ALDH1A1 (0.66) | ALDH1A1LMNAKDM4ETDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | ALDH1A1 3556/4885LMNA 968/4885KDM4E 2066/4885 |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | CACNA1B, CACNG6, SCN5A | ALDH1A1 3556/4885LMNA 968/4885KDM4E 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.